SEC Form 4	
------------	--

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVA

	OVAL							
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] Scimeca Dario			2. Issuer Name and Ticker or Trading Symbol <u>PRECISION BIOSCIENCES INC</u> [DTIL]		ationship of Reporting Pe (all applicable) Director	10% Owner				
(Last) C/O PRECISIO	(First) DN BIOSCIEN	(Middle) CES, INC.	3. Date of Earliest Transaction (Month/Day/Year) 06/07/2023	X	Officer (give title below) General Counsel a	Other (specify below) nd Secretary				
302 E PETTIGREW STREET, SUITE A-100		, SUITE A-100	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	,					
(Street) DURHAM	NC	27701			Form filed by More the Person	an One Reporting				
(City)	(State)	(Zip)	Rule 10b5-1(c) Transaction Indication							
			X Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.							

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	ecution Date, ny Code (Instr. onth/Day/Year)		4. Securities / Disposed Of (5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
					Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		
Common Stock	06/07/2023		М		22,727 ⁽¹⁾	A	(2)	72,790	D	
Common Stock	06/07/2023		М		9,044(1)	A	(2)	81,834	D	
Common Stock	06/08/2023		S ⁽³⁾		13,361	D	\$0.75	68,473	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

						·		<u> </u>							
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (li 8)		of Deri Sec Acq (A) Disp of (I	oosed D) tr. 3, 4	Expiration Date (Month/Day/Year)		and 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownershi (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Units	(2)	06/07/2023		М			22,727	(4)	(4)	Common Stock	22,727	\$0.00	0	D	
Restricted Stock Units	(2)	06/07/2023		М			9,044	(5)	(5)	Common Stock	9,044	\$0.00	9,045	D	

Explanation of Responses:

1. Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on June 7, 2023.

2. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share.

3. The sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover, with shares sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs.

4. On June 7, 2021 the Reporting Person was granted RSUs, which vest in two equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

5. On June 7, 2021 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Remarks:

<u>/s/ John Alexander Kelly,</u> <u>Attorney-in-Fact for Dario</u> <u>Scimeca</u>

06/09/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.